Clinical Trial Data (BDC-1001) - Early signs of disease control were observed, even below the target exposure level[1] - Durable disease control (SD or PR) was noted in 13 out of 40 evaluable subjects (32.5%)[1] - A subject with metastatic CRC confirmed PR at 36 weeks, maintained for >52 weeks[3] - In a case study, a 66-year-old male with metastatic adenocarcinoma of colon experienced a 32% and 37% decrease in tumor size at 12 weeks[19] - A clinical trial subject with breast cancer on BDC-1001 showed a two-fold increase in CD8+ T cell infiltration and activation compared to baseline[22] Financial Status - The company had a cash balance of $209.6 million as of September 30, 2022[4] - The cash on hand is expected to fund key milestones through 2025[4] Pipeline and Programs - The company is developing BDC-1001, a HER2-targeting Boltbody™ Immune-stimulating Antibody Conjugate (ISAC)[7, 13] - The company is also developing BDC-3042, a Dectin-2 agonist antibody[13, 37] - The company is pursuing multiple next-generation ISAC programs with collaborators[13]
Bolt Biotherapeutics (BOLT) Investor Presentation - Slideshow